Assessment of paraoxonase activity and lipid peroxidation levels in diabetic and senile subjects suffering from cataract

Clinical Biochemistry

Volumn 40, Issue 9-10, 2007, Pages 705-709

  Hashim, Zehra ^a   Zarina, Shamshad ^a  

^a UNIVERSITY OF KARACHI   (Pakistan)

Author keywords

Diabetic cataract; Lipid peroxidation; Malondialdehyde; Oxidative stress; Paraoxonase activity; Senile cataract

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; ARYLESTERASE; MALONALDEHYDE; ORAL ANTIDIABETIC AGENT; OXIDIZED LOW DENSITY LIPOPROTEIN; PARAOXON; PHENYLACETIC ACID;

ADULT; AGED; ANALYSIS OF VARIANCE; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC PATIENT; ELDERLY CARE; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FEMALE; HUMAN; LIPID PEROXIDATION; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK FACTOR; SENILE CATARACT;

ADULT; AGED; AGING; ARYLDIALKYLPHOSPHATASE; CARBOXYLIC ESTER HYDROLASES; CATARACT; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DIABETES MELLITUS, TYPE 2; HUMANS; LIPID PEROXIDATION; LIPOPROTEINS, LDL; MALONDIALDEHYDE; MIDDLE AGED; TRIGLYCERIDES;

EID: 34249658584     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2007.03.015     Document Type: Article

References (44)

1. Vision research: A national plan 1999-2000, Report of the National Advisory Council, National Eye Institute; 1998. p. 59
2. Kupfer C., Underwood B., and Gillen T. Leading cause of visual impairment worldwide. In: Alberts D.M., and Jakobiec F.A. (Eds). Principles and practice of ophthalmology (1994), WB. Saunders Co, Philadelphia 1249-1255
3. Truscott R.J. Age-related nuclear cataract - oxidation is the key. Exp. Eye Res. 80 (2005) 709-725
4. Vinson J.A. Oxidative stress in cataracts. Pathophysiology 13 (2006) 151-162
5. Berlett B.S., and Stadtman E.R. Protein oxidation in aging, disease, and oxidative stress. J. Biol. Chem. 272 (1997) 20313-20316
6. Institute of Medicine. Antioxidant and related compounds. Dietary reference intakes for vitamin C, vitamin E, selenium and carotenoids (2000), National Academy Press, Washington, DC
7. Ozmen B., Ozmen D., Erkin E., Guner I., Habif S., and Bayindir O. Lens superoxide dismutase and catalase activities in diabetic cataract. Clin. Biochem. 35 (2002) 69-82
8. Ates N.A., Yildirim O., Tamer L., Unlu A., Ercan B., Muslu N., et al. Plasma catalase activity and malondialdehyde level in patients with cataract. Eye 18 (2004) 785-788
9. Donma O., Yorulmaz E., Pekel H., and Suyugul N. Blood and lens lipid peroxidation and antioxidant status in normal individuals, senile and diabetic cataractous patients. Curr. Eye Res. 25 (2002) 9-16
10. Hashim Z., and Zarina S. Antioxidant markers in human senile and diabetic cataractous lenses. J. Coll. Physicians Surg. Pak. 16 (2006) 637-640
11. La Du B.N. Structural and function diversity of paraoxonases. Nat. Med. 2 (1996) 1186-1187
12. Mackness M.I., Mackness B., Durrington P.N., Connelly P.W., and Hegele R.A. Paraoxonase: biochemistry, genetics and relationship to plasma lipoproteins. Curr. Opin. Lipidol. 7 (1996) 69-76
13. Ng C.J., Wadleigh D.J., Gangopadhay A., Hama S., Grijalva V., Navab M., et al. Paraoxonase-2 is a ubiquitously expressed protein with antioxidant properties and is capable of preventing cell-mediated oxidative modification of low density lipoprotein. J. Biol. Chem. 276 (2001) 44444-44449
14. Berliner J.A., Navab M., Fogelman A.M., Frank J.S., Demer L.L., Edwards P.A., et al. Atherosclerosis: basic mechanisms. Oxidation, inflammation, and genetics. Circulation 91 (1995) 2488-2496
15. Aviram M., Rosenblat M., Billecke S., Erogul J., Sorenson R., Bisgaier C.L., et al. Human serum paraoxonase (PON 1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants. Free Radic. Biol. Med. 26 (1999) 892-904
16. Jakubowski H. Calcium-dependent human serum homocysteine thiolactone hydrolase: a protective mechanism against protein N-homocysteinylation. J. Biol. Chem. 275 (2000) 3957-3962
17. Josse D., Lockridge O., Xie W., Bartels C.F., Schopfer L.M., and Masson P. The active site of human paraoxonase (PON1). J. Appl. Toxicol. 21 (2001) S7-S11
18. Navab M., Hama-Levy S., Van-Lenten B.J., Fonarow G.C., Cardinez C.J., Castellani L.W., et al. Mildly oxidized LDL induces an increased apolipoprotein J/paraoxonase ratio. J. Clin. Invest. 99 (1997) 2005-2019
19. McElveen J., Mackness M.I., Colley C.M., Peard T., Warner S., and Walker C.H. Distribution of paraoxon hydrolytic activity in the serum of patients after myocardial infarction. Clin. Chem. 32 (1986) 671-673
20. Abbott C.A., Mackness M.I., Kumar S., Boulton A.J., and Durrington P.N. Serum paraoxonase activity, concentration and phenotype distribution in diabetes mellitus and its relationship to serum lipids and lipoproteins. Arterioscler. Thromb. Vasc. Biol. 15 (1995) 1812-1818
21. Mackness B., Mackness M.I., Arrol S., Turkie W., Julier K., Abuasha B., et al. Serum paraoxonase (PON1) 55 and 192 polymorphism and paraoxonase activity and concentration in non-insulin dependent diabetes mellitus. Atherosclerosis 139 (1998) 341-349
22. Sakai T., Matsuura B., and Onji M. Serum paraoxonase activity and genotype distribution in Japanese patients with diabetes mellitus. Intern. Med. 37 (1998) 581-584
23. Dantoine T.F., Debord J., Charmes J.P., Merle L., Marquet P., Lachatre G., et al. Decrease of serum paraoxonase activity in chronic renal failure. J. Am. Soc. Nephrol. 9 (1998) 2082-2088
24. Baskol G., Demir H., Baskol M., Kilic E., Ates F., Kocer D., et al. Assessment of paraoxonase 1 activity and malondialdehyde levels in patients with rheumatoid arthritis. Clin. Biochem. 38 (2005) 951-955
25. Raiszadeh F., Solati M., Etemadi A., and Azizi F. Serum paraoxonase activity before and after treatment of thyrotoxicosis. Clin. Endocrinol. 60 (2004) 75-80
26. Baskol G., Karakucuk S., Oner A.O., Baskol M., Kocer D., Mirza E., et al. Serum paraoxonase 1 activity and lipid peroxidation levels in patients with age-related macular degeneration. Ophthalmologica 220 (2006) 12-16
27. Gan K.N., Smolen A., Eckerson H.W., and La Du B.N. Purification of human serum paraoxonase/arylesterase. Drug Metab. Dispos. 19 (1991) 100-106
28. Grotto D., Santa Maria L.D., Boeira S., Valentini J., Charao M.F., Moro A.M., et al. Rapid quantification of malondialdehyde in plasma by high performance liquid chromatography-visible detection. J. Pharm. Biomed. Anal. 43 (2007) 619-624
29. Ahotupa M., and Vasankari T.J. Baseline diene conjugation in LDL lipids: an indicator of circulating oxidized LDL. Free Radic. Biol. Med. 27 (1999) 1141-1150
30. Halliwel B. Role of free radicals in the neurodegenerative diseases: therapeutic implications for antioxidant treatment. Drugs Aging 18 (2001) 685-716
31. Kregel K.C., and Zhang H.J. An integrated view of oxidative stress in aging: basic mechanisms, functional effects and pathological considerations. Am. J. Physiol. Regul. Integr. Comp. Physiol. 292 (2007) R18-R36
32. Ottonello S., Foroni C., Carta A., Petrucco S., and Maraini G. Oxidative stress and age-related cataract. Ophthalmologica 214 (2000) 78-85
33. McCarty C., and Taylor H.R. Light and risk of age related eye diseases. In: Taylor A. (Ed). Nutritional and environmental influence on the eye (1999), CRC Press, Boca Raton, FL 135-150
34. Maritim A.C., Sanders R.A., and Watkins III J.B. Diabetes, oxidative stress, and antioxidants: a review. J. Biochem. Mol. Toxicol. 17 (2003) 24-38
35. Ikeda Y., Suehiro T., Inoue M., Nakauchi Y., Morita T., Arii K., et al. Serum paraoxonase activity and its relationship to diabetic complications in patients with non-insulin-dependent diabetes mellitus. Metabolism 47 (1998) 598-602
36. Mackness B., Durrington P.N., Abuashia B., Boulton A.J., and Mackness M.I. Low paraoxonase activity in type II diabetes mellitus complicated by retinopathy. Clin. Sci. 98 (2000) 355-363
37. Orhan H., Marol S., Hepsen I.F., and Sahin G. Effects of some probable antioxidants on selenite-induced cataract formation and oxidative stress-related parameters in rats. Toxicology 139 (1999) 219-232
38. Babizhayev M.A., Deyev A.I., Yermakova V.N., Brikman I.V., and Bours J. Lipid peroxidation and cataracts: N-acetylcarnosine as a therapeutic tool to manage age-related cataracts in human and in canine eyes. Drugs R. D. 5 (2004) 125-139
39. Cerne D., and Lukac-Bajalo J. Oxidative stress assays for disease risk stratification. Acta Pharm. 56 (2006) 1-17
40. Mullarkey C.J., Edelstein D., and Brownlee M. Free radical generation by early glycation products: a mechanism for accelerated atherogenesis in diabetes. Biochem. Biophys. Res. Commun. 173 (1990) 932-939
41. Jaouad L., de Guise C., Berrougui H., Cloutier M., Isabelle M., Fulop Jr. T., et al. Age-related decrease of high-density lipoproteins antioxidant activity is due to an alteration in the PON1's free sulfhydryl groups. Atherosclerosis 185 (2006) 191-200
42. Milochevitch C., and Khalil A. Study of the paraoxonase and platelet-activating factor acetylhydrolase activities with aging. Prostaglandins Leukot. Essent. Fatty Acids 65 (2001) 241-246
43. Seres I., Paragh G., Deschene E., Fulop Jr. T., and Khalil A. Study of factors influencing the decreased HDL associated PON1 activity with aging. Exp. Gerontol. 39 (2004) 59-66
44. Hedrick C.C., Thorpe S.R., Fu M.X., Harper C.M., Yoo J., Kim S.M., et al. Glycation impairs high-density lipoprotein function. Diabetologia 43 (2000) 312-320